UNSPSC 51294207: Reboxetine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 947S0YZ36I. European Medicines Agency schedules Reboxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG. Reboxetine generally arises in the molecular formula C19H23NO3.

UNSPSC 51294207 Reboxetine (Commodity) shows minimal alignment with recent state and local procurement activity. The single sourced opportunity, Seminole County, Florida IFB60459723LAS, solicits naloxone and drug deactivation systems rather than reboxetine—a pharmaceutical product in a different therapeutic category. Reboxetine, a selective norepinephrine reuptake inhibitor used in depression treatment, does not appear in current state and local solicitations tracked under this code. The mismatch suggests either misclassification in the source data or that reboxetine procurement through state and local bodies is not active in the recent market.

Seminole County's naloxone procurement represents opioid-overdose response supply rather than psychiatric medication. The IFB, released June 30, 2026 with a response deadline of July 26, 2023 (date inconsistency present in source), targets 1,900 annual units of naloxone and 800 drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract offers a two-year initial term with one-year renewal option and includes standard compliance requirements such as E-Verify verification, drug-free workplace certification, and insurance coverage. No geographic concentration of reboxetine procurement activity or additional state and local opportunities under this code are present in the recent-opportunities block. Unless reboxetine procurement is specifically embedded in larger pharmaceutical or medication-supply RFPs at state health departments or school districts—opportunities not reflected in the available source—this code warrants low priority for business development.